Last reviewed · How we verify

NCT05343026

Efficacy of Hearing-aid Treatment for Patients With Tinnitus and Co-existing Hearing Loss

Status unknown NA Last updated 25 April 2022
What this trial tests

NA trial testing Hearing aids in Tinnitus, Subjective in 62 participants. Status unknown.

Timeline
1 July 2022
Primary endpoint
1 July 2023
1 December 2023

Quick facts

Lead sponsorEye & ENT Hospital of Fudan University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment62
Start date1 July 2022
Primary completion1 July 2023
Estimated completion1 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

Eye & ENT Hospital of Fudan University

Who can join

Adults 18 to 70, any sex, with Tinnitus, Subjective or Hearing Loss, High-Frequency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Considering the extent to which HAs play a role in sound perception and residual hearing preservation among patients with tinnitus and co-existing HL remains a lack of compelling extensive evidence, investigators designed this single-blind, 6-months randomized, controlled trial with two parallel groups. One is the HA treatment group, and the other is the waiting list control (WLC) group which receives no interventions during this period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Efficacy of hearing aid treatment on sound perception and residual hearing preservation in patients with tinnitus and coexisting hearing loss: study protocol for a randomized controlled trial.
    Li P, Tang D, Wu Y, Yin Y, et al · · 2022 · PMID 36575531 · DOI 10.1186/s13063-022-07014-0

Verify or expand the search:

Other trials of Hearing aids

Trials testing the same drug.

Other recruiting trials for Tinnitus, Subjective

Currently open trials in the same condition.

Other Eye & ENT Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05343026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing